Bionsight Enters R&D Collaboration Agreement with Astellas for First-in-Class Autoimmune Disorder Therapy
News originally published by
EIN PresswirePartnership targets autoimmune disorders via the innate immune pathway, aiming for a preclinical candidate
SF, CA, UNITED STATES, November 19, 2026 /EINPresswire.com/ -- Bionsight, an AI-powered chemoproteomics drug discovery company, today announced that it has entered into a global R&D collaboration agreement with Astellas Pharma Inc. (Astellas), a global pharmaceutical company headquartered in Tokyo, Japan and has begun joint research aimed at exploring a first-in-class therapy for autoimmune disorders.The agreement took effect in November 2026. Bionsight will lead the project, overseeing AI-driven molecular design, target validation using its proprietary Javelin™ platform, and lead optimization. Astellas will contribute its data and expertise and provide development guidance and support in accordance with the collaboration agreement.
The collaboration builds on Bionsight’s platform combining AI molecular design and chemoproteomics, with the goal of bringing a new approach to treating autoimmune disorders. The companies plan to develop a first-in-class therapy that targets the innate immune pathway, working through a different mechanism from existing treatments.
The project was selected for the Global Collaboration R&D track of the 2026 SME Technology Innovation Development Program, run by the Korea Technology and Information Promotion Agency for SMEs (TIPA).
Bionsight develops platforms that combine AI and chemoproteomics to identify and validate drug targets. Its core platform, Javelin™, analyzes how a drug interacts with more than 7,000 proteins at once without chemically modifying the drug, and pinpoints the exact sites where the drug binds. By showing early in development which proteins a drug actually acts on in the body, the platform improves the accuracy of target discovery and lead optimization.
“This partnership with Astellas represents a significant milestone for Bionsight as we translate our platform technologies into tangible global drug development programs,” said Heejung Yang, CEO of Bionsight. “By combining our AI-chemoproteomics capabilities with Astellas’ global expertise, we aim to deliver innovative treatments for patients with autoimmune disorders.”
About Bionsight
Founded in 2019, Bionsight develops AI- and chemoproteomics-based platforms to identify and validate therapeutic targets and accelerate drug discovery. The company is headquartered in Chuncheon, South Korea.
The company is led by a team with expertise spanning pharmacy, physics and mathematical sciences. CEO Heejung Yang is a professor at Kangwon National University’s College of Pharmacy and holds a Ph.D. in pharmacy from Seoul National University. CTO Hojin Yoo earned a Ph.D. in physics from the University of Wisconsin and has worked as a researcher at UC Berkeley and the U.S. Fermi National Accelerator Laboratory (Fermilab). CSO Namgil Lee is an associate professor of statistics at Kangwon National University, holds a Ph.D. in mathematical sciences from Korea Advanced Institute of Science and Technology (KAIST), and was a researcher at RIKEN’s Brain Science Institute (currently known as the RIKEN Center for Brain Science) in Japan.
Team Cookie Official
Team Cookie
Visit us on social media:
LinkedIn
Facebook
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
